MOBERG PHARMA SIGNS DISTRIBUTION AGREEMENT IN MIDDLE EAST AND NORTH AFRICA

Moberg Pharma AB (OMX: MOB) today signed an exclusive agreement with Leosons
International to distribute Moberg’s Kerasal Nail™ in MENA (Middle East and
North Africa). Leosons has been successfully distributing Moberg’s JointFlex®
brand in the Middle East for almost 10 years.  Leosons intends to launch Kerasal
Nail™ in 2014.
The agreement encompasses sixteen markets, including Egypt, Iraq, Saudi Arabia,
Tunisia and UAE.
About Kerasal Nail™ and nail disease
Kerasal Nail™ is a topical treatment used to treat nail disease. Launched in
late 2010, it quickly became the market leader in the Nordics and recently also
the best-selling product in its category in the U.S. The international launch is
under way via a proprietary sales organization in the U.S. and ten partners that
hold rights for 50 markets, including the major EU markets, China, Turkey and
Russia. Kerasal Nail™ is a prescription-free, over-the-counter product sold
under the names Kerasal Nail™, Naloc™/Nalox™ and Emtrix®. Safety and efficacy
have been demonstrated in several clinical studies including more than 600
patients. Kerasal Nail™ has a unique and rapid mechanism of action which brings
visible improvements within 2-4 weeks of treatment. Nail fungus is the most
common nail disease. The condition afflicts approximately 10 percent of the
population and is more common among the elderly. It is generally recognized that
there is a need for new efficacious and safe topical treatments.
For further information, please contact:
Peter Wolpert, CEO
Telephone: +46 8 522 307 00; Mobile: +46 707 35 71 35; E-mail:
peter.wolpert@mobergpharma.se

Peter Östling, IR
Mobile: +46 76 314 09 78; Email: peter.ostling@mobergpharma.se
About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 am (CET) on October 25, 2013.

About Moberg Pharma AB
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
its own sales organization in the US and sales through distributors in more than
40 countries. The company’s product portfolio includes topical products for the
treatment of skin disorders and pain under the brands Kerasal®, Jointflex®,
Kerasal Nail®and Kaprolac®. Kerasal Nail®(Nalox™ in many markets) is the leading
product for the treatment of nail disorders in the Nordic market. The portfolio
is developed further through acquisitions and in-licensing of products as well
as product development with focus on innovative drug delivery based on proven
compounds. Moberg Pharma has offices in Stockholm and New Jersey and the
company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX
Nordic Exchange Stockholm. For further information, please visit:
www.mobergpharma.se.

About Leosons International AB
Leosons International distributes pharmaceuticals, OTC products and Medical
Equipment over 6 continents, with a focus on the MENA region (Middle East and
North Africa). For further information, please visit:
www.leosonsinternational.com